Manufacturer record
Cureza Healthcare pvt. Ltd. A.B.Road Girwai: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
1 batch manufactured by Cureza Healthcare pvt. Ltd. A.B.Road Girwai was declared Not of Standard Quality in June 2025. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: CHT23320, Curacet Tablets (Cetirizine Hydrochloride) (exp Sep 2025). FDA Lab, Mumbai (CDSCO lab) found it not of standard quality: Almost all the tablets received for analysis show Grey coloured spots all over the surface of the tablet, when observed in normal day light. Listed in the June 2025 alert.
Records by type
1 record linked to Cureza Healthcare pvt. Ltd. A.B.Road Girwai in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Curacet Tablets (Cetirizine Hydrochloride) | Batch CHT23320Mfg Oct 2023 · Exp Sep 2025 | Almost all the tablets received for analysis show Grey coloured spots all over the surface of the tablet, when observed in normal day light with unaided eyes.Description | FDA Lab , MumbaiCDSCO lab | Jun 2025 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.